Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 03, 2015 4:33 PM ET

Healthcare Providers and Services

Company Overview of BDI Pharma, Inc.

Company Overview

BDI Pharma, Inc. distributes specialty biotherapeutic products. It offers albumin products, injectables, subcutaneous implants, intravenous immune globulin, subcutaneous Ig injectable Ig, coagulation factor, fibrinogen concentrates, anti-thrombin III, vaccines, generic specialty products, branded specialty products, supportive care products, antibiotics, and diluents. The company was formerly known as Blood Diagnostics, Inc. and changed its name to BDI Pharma, Inc. in February 2009. BDI Pharma, Inc. was founded in 1995 and is based in Columbia, South Carolina.

120 Research Drive

Columbia, SC 29203

United States

Founded in 1995





Key Executives for BDI Pharma, Inc.

Chief Information Officer
Assistant Vice President of Marketing
Vice President
Director of Wholesaler Relations/Vaccine Portfolio
Compensation as of Fiscal Year 2015.

BDI Pharma, Inc. Key Developments

BDI Pharma, Inc. Receives Three-Year Consignment Contract with National GPO Premier, Inc

BDI Pharma, Inc. announced that it was awarded the contract to offer GPO compliant consignment services to acute care members of Premier, Inc. through its industry renowned program, BDIVantage Plus. The contract is in effect January 1, 2015 through December 31, 2017. BDI's consignment program has been a mainstay among their acute care customers for over fifteen years. With one of the simplest structures on the market for any consignment program, BDIVantage Plus is a cost effective solution for inventory management of specialty pharmaceuticals.

BDI Pharma Launches The MERREM Commitment Program with AstraZeneca for Secure Access to Anti-Bacterial Product MERREM(R) I.V

BDI Pharma announced the launch of The MERREM Commitment Program(TM) with AstraZeneca, an assurance initiative offering customers security in product availability through contracted access to the original, branded MERREM(R)I.V. from AstraZeneca. Along with this innovative new partnership, BDI Pharma was awarded the status of Authorized Distributor of Record (ADR) for AstraZeneca and is the sole and exclusive distributor of contracted MERREM(R)I.V. in the United States.

BDI Pharma, Inc. Reports Revenue Results for the Third Quarter of 2013

BDI Pharma, Inc. reported revenue results for the third quarter of 2013. The company reported sales revenues for the quarter, representing a 39% increase compared to the same time period in 2012. This continues the upward trend from the second quarter driving overall growth for the year to over 38%.

Similar Private Companies By Industry

Company Name Region
Maris Grove, Inc. United States
Pacific Dental Management United States
Fountain Valley Regional Hospital and Medical Center, Inc. United States
Aetna Health Inc. (Colorado) United States
Lifesquare, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BDI Pharma, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at